Imeglimin (hydrochl...

Imeglimin (hydrochloride)

Imeglimin (hydrochloride)

Min.Order / FOB Price:Get Latest Price

1 Gram

Negotiable

  • Min.Order :1 Gram
  • Purity: 99
  • Payment Terms : L/C,D/P,T/T

Keywords

775351-61-6 EMD 387008 hydrochloride Imeglimin

Quick Details

  • Appearance:white power
  • Application:anticancer
  • PackAge:DRUMS/CARTON
  • ProductionCapacity:10|Metric Ton|Week
  • Storage:dry place
  • Transportation:BY AIR or SEA

Superiority:

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.
Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.
To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Details:

Imeglimin is the first in a new tetrahydrotriazine-containing class of oral antidiabetic agents, the glimins. It has been shown to act on the liver, muscle and pancreatic β-cells to uniquely target the key defects of type 2 diabetes. Two studies were performed to compare the safety and efficacy of imeglimin with metformin and placebo on glycaemic control in type 2 diabetes patients.

The results from both studies confirm that imeglimin displays a superior benefit : risk profile compared with metformin in type 2 diabetes patients. The encouraging tolerability profile of imeglimin could make it suitable for combination with other classes of antidiabetic agents and may increase availability to a wider patient population.

Imeglimin was found to be as effective as metformin at reducing the AUC(PG) and AUC(0-6h) , FPG and HbA1c. Imeglimin exhibited a favourable tolerability profile in comparison to metformin.

Therefore, multiple preclinical experiments involving both in vivo and in vitro approaches have revealed a consistent and strong effect of Imeglimin to improve pancreatic β-cell function by amplifying insulin release in an exclusively glucose-dependent fashion.

 

View All
Visit Store

You Might Also Like

Related Searches

Contact Supplier

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View